Nova TheraNostics is developing a new and uniquely differentiated contrast agent for use with magnetic resonance imaging (MRI) that will not only be highly competitive relative to existing agents, but will also enable the extension of MRI into new indications not currently served by this imaging modality. NTN’s contrast agent, Nanobrite™, will be the only gadolinium-based contrast agent (GBCA) capable of serving some of these new MRI diagnostic indications, garnering for itself a large, new, captive market in addition to significant penetration of the existing GBCA market.